Q1 2025 Management View CEO Chris Viehbacher highlighted Biogen's evolving portfolio, with newer products such as LEQEMBI, SKYCLARYS, and ZURZUVAE now comprising 45% of product revenue. He emphasized ...

Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.

Sales of multiple sclerosis drugs such as Tecfidera fell 11% to $953 million. Sales of rare disease drugs, including ...

Medications like donanemab (Kisunla) and lecanemab (Leqembi) target amyloid plaques that build up in the brain due to ...

A report from the Alzheimer’s Association says new treatments and blood tests could change how doctors detect and treat the ...

In addition, Eisai must conduct a post-authorization safety study, including setting up a patient registry for the European Union. Now each European country must set its own rules for access and ...

Burdened by competitive pressures for its stalwart multiple sclerosis franchise, Biogen has weathered years of sales declines ...

Announcing first-quarter results, Biogen CEO Chris Viehbacher admitted that tariffs are “a new topic for us,” but said he ...

We recognize and have recognized for some time that Alzheimer’s disease is a public health crisis,” said Meggie Gaskins.

Shares of the drugmaker rose 2.2%. Biogen has been doubling down on its Alzheimer's drug Leqembi, but it has failed to live up to lofty expectations due to concerns over cost, efficacy and side ...

UK regulators are set to review a proposed label update for Eisai (TYO: 4523) and Biogen’s (Nasdaq: BIIB) Alzheimer’s drug ...

Biogen Inc (BIIB) reports a 6% revenue increase driven by new product launches, despite facing competitive pressures in its MS franchise.